Drug Profile
Urocortin 2
Alternative Names: NBI 69734; UCN 2; urocortin IILatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Clayton Foundation for Research
- Developer Neurocrine Biosciences
- Class Hormones; Peptides; Small molecules
- Mechanism of Action Corticotropin-releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute heart failure; Alzheimer's disease; Heart failure; Obesity
Most Recent Events
- 17 May 2012 Pharmacodynamics and adverse events data from a phase I/II trial in Acute decompensated heart failure released by Neurocrine Biosciences
- 31 Mar 2012 Neurocrine Biosciences completes the phase I/II UNICORN trial in Acute decompensated heart failure in New Zealand
- 28 Oct 2010 Phase-II clinical trials in Congestive heart failure in United Kingdom (IV)